Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLMD
Previous Symbol
CUSIPN/A
Phone972-3693-8448
Debt
Debt-to-Equity RatioN/A
Current Ratio43.47
Quick Ratio43.47
Price-To-Earnings
Trailing P/E Ratio-8.48
Forward P/E Ratio-17.31
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.09 million
Price / Sales121.30
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.24 per share
Price / Book6.70
Profitability
EPS (Most Recent Fiscal Year)($0.98)
Net Income$-12,290,000.00
Net Margins-423.62%
Return on Equity-18.55%
Return on Assets-17.52%
Miscellaneous
Employees17
Outstanding Shares15,910,000
Market Cap$132.20 million
OptionableOptionable
Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions
What is Galmed Pharmaceuticals' stock symbol?
Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals' earnings last quarter?
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) posted its earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.09. The biopharmaceutical company earned $1.50 million during the quarter, compared to analysts' expectations of $0.30 million. Galmed Pharmaceuticals had a negative net margin of 423.62% and a negative return on equity of 18.55%. View Galmed Pharmaceuticals' Earnings History.
When is Galmed Pharmaceuticals' next earnings date?
What price target have analysts set for GLMD?
7 brokers have issued 1 year price targets for Galmed Pharmaceuticals' stock. Their predictions range from $20.00 to $59.00. On average, they expect Galmed Pharmaceuticals' share price to reach $37.6250 in the next year. This suggests a possible upside of 352.8% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.
What is the consensus analysts' recommendation for Galmed Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.
Has Galmed Pharmaceuticals been receiving favorable news coverage?
Press coverage about GLMD stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Galmed Pharmaceuticals' key competitors?
Some companies that are related to Galmed Pharmaceuticals include Ra Pharmaceuticals (RARX), NuCana (NCNA), CymaBay Therapeutics (CBAY), Basilea Pharmaceutica (BPMUF), Aurinia Pharmaceuticals (AUPH), ChemoCentryx (CCXI), Flexion Therapeutics (FLXN), Theratechnologies (THERF), Innate Pharma (IPHYF), Prothena (PRTA), Epizyme (EPZM), Corium International (CORI), Arvinas (ARVN), Beyondspring (BYSI) and Rigel Pharmaceuticals (RIGL).
Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the folowing people:
- Mr. Yohai Stenzler, CFO & Controller (Age 35)
- Mr. Guy Nehemya, VP of Operations (Age 33)
- Dr. Liat Hayardeny, Chief Scientific Officer (Age 51)
- Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 35)
- Dr. Tali Gorfine, Chief Medical Officer (Age 48)
Who are Galmed Pharmaceuticals' major shareholders?
Galmed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (5.35%), Ibex Investors LLC (2.63%), Baker BROS. Advisors LP (2.04%), Morgan Stanley (0.83%), Point72 Asset Management L.P. (0.72%) and P.A.W. Capital Corp (0.57%).
Which major investors are selling Galmed Pharmaceuticals stock?
GLMD stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Baker BROS. Advisors LP, Morgan Stanley and P.A.W. Capital Corp.
Which major investors are buying Galmed Pharmaceuticals stock?
GLMD stock was acquired by a variety of institutional investors in the last quarter, including Ibex Investors LLC, Vivo Capital LLC, ARK Investment Management LLC, Wells Fargo & Company MN and Trellus Management Company LLC.
How do I buy shares of Galmed Pharmaceuticals?
Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Galmed Pharmaceuticals' stock price today?
One share of GLMD stock can currently be purchased for approximately $8.31.
How big of a company is Galmed Pharmaceuticals?
Galmed Pharmaceuticals has a market capitalization of $132.20 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.
What is Galmed Pharmaceuticals' official website?
How can I contact Galmed Pharmaceuticals?
Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.
MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
